$6.89 Billion is the total value of Bellevue Group AG's 202 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CLDX | CELLDEX THERAPEUTICS INC | $64,764,000 | -19.3% | 1,800,000 | 0.0% | 0.94% | -11.7% | |
| COO | COOPER COS INC | $30,359,022 | +12.9% | 81,313 | 0.0% | 0.44% | +23.5% | |
| EPIX | ESSA PHARMA INC | $23,458,792 | +17.9% | 7,898,583 | 0.0% | 0.34% | +28.8% | |
| RMD | RESMED INC | $21,521,242 | +5.2% | 98,275 | 0.0% | 0.31% | +15.1% | |
| PROCEPT BIOROBOTICS CORP | $21,059,083 | -31.6% | 741,517 | 0.0% | 0.31% | -25.2% | ||
| WVE | WAVE LIFE SCIENCES LTD | $19,461,003 | -38.1% | 4,494,458 | 0.0% | 0.28% | -32.5% | |
| TXG | 10X GENOMICS INC | $18,117,579 | +53.1% | 324,746 | 0.0% | 0.26% | +67.5% | |
| DOCS | DOXIMITY INCcl a | $14,524,988 | -3.5% | 448,579 | 0.0% | 0.21% | +5.5% | |
| KOS | KOSMOS ENERGY LTD | $2,368,152 | +17.0% | 318,300 | 0.0% | 0.03% | +25.9% | |
| CYTK | CYTOKINETICS INC | $1,907,298 | -23.2% | 54,200 | 0.0% | 0.03% | -15.2% | |
| KRYS | KRYSTAL BIOTECH INC | $1,465,098 | +1.1% | 18,300 | 0.0% | 0.02% | +10.5% | |
| KRTX | KARUNA THERAPEUTICS INC | $1,325,972 | -7.6% | 7,300 | 0.0% | 0.02% | 0.0% | |
| VRDN | VIRIDIAN THERAPEUTICS INC | $1,172,784 | -12.9% | 46,100 | 0.0% | 0.02% | -5.6% | |
| CAH | CARDINAL HEALTH INC | $800,300 | -1.8% | 10,600 | 0.0% | 0.01% | +9.1% | |
| MRUS | MERUS N V | $840,880 | +18.9% | 45,700 | 0.0% | 0.01% | +33.3% | |
| SPY | SPDR S&P 500 ETF TRtr unit | $736,902 | +7.0% | 1,800 | 0.0% | 0.01% | +22.2% | |
| DNLI | DENALI THERAPEUTICS INC | $714,240 | -17.2% | 31,000 | 0.0% | 0.01% | -9.1% | |
| XNCR | XENCOR INC | $708,406 | +7.1% | 25,400 | 0.0% | 0.01% | +11.1% | |
| RCKT | ROCKET PHARMACEUTICALS INC | $626,958 | -12.5% | 36,600 | 0.0% | 0.01% | -10.0% | |
| GOOG | ALPHABET INCcap stk cl c | $624,000 | +17.2% | 6,000 | 0.0% | 0.01% | +28.6% | |
| ARWR | ARROWHEAD PHARMACEUTICALS IN | $541,020 | -37.4% | 21,300 | 0.0% | 0.01% | -27.3% | |
| INBX | INHIBRX INC | $560,439 | -23.4% | 29,700 | 0.0% | 0.01% | -20.0% | |
| SEER | SEER INC | $525,473 | -33.4% | 136,133 | 0.0% | 0.01% | -20.0% | |
| XOP | SPDR SER TRs&p oilgas exp | $497,601 | -6.1% | 3,900 | 0.0% | 0.01% | 0.0% | |
| MCHI | ISHARES TRmsci china etf | $204,549 | +5.0% | 4,100 | 0.0% | 0.00% | 0.0% | |
| OPT | OPTHEA LTDsponsored ads | $186,120 | -20.7% | 47,000 | 0.0% | 0.00% | 0.0% | |
| GDXJ | VANECK ETF TRUSTjunior gold mine | $197,500 | +10.8% | 5,000 | 0.0% | 0.00% | +50.0% | |
| IPGP | IPG PHOTONICS CORP | $129,476 | +30.3% | 1,050 | 0.0% | 0.00% | +100.0% | |
| JMIA | JUMIA TECHNOLOGIES AGsponsored ads | $59,220 | +2.5% | 18,000 | 0.0% | 0.00% | 0.0% | |
| ASR | GRUPO AEROPORTUARIO DEL SUREspon adr ser b | $41,373 | +26252.2% | 135 | 0.0% | 0.00% | – | |
| TSM | TAIWAN SEMICONDUCTOR MFG LTDsponsored ads | $71,625 | +5634.6% | 770 | 0.0% | 0.00% | – | |
| EVTC | EVERTEC INC | $24,941 | +4.2% | 739 | 0.0% | 0.00% | – | |
| INFY | INFOSYS LTDsponsored adr | $19,707 | -4.4% | 1,130 | 0.0% | 0.00% | – | |
| EQIX | EQUINIX INC | $28,842 | +10.1% | 40 | 0.0% | 0.00% | – | |
| UMC | UNITED MICROELECTRONICS CORPspon adr new | $23,634 | +32.3% | 2,698 | 0.0% | 0.00% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- BB Biotech AG #1
- Bellevue Asset Management AG #2
- Bellevue Asset Management (UK) Ltd. #3
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| IONIS PHARMACEUTICALS INC | 31 | Q3 2023 | 9.3% |
| Vertex Pharmaceuticals Incorporated | 31 | Q3 2023 | 5.9% |
| NEUROCRINE BIOSCIENCES INC | 31 | Q3 2023 | 5.7% |
| Incyte Corporation | 31 | Q3 2023 | 5.4% |
| INTUITIVE SURGICAL INC | 31 | Q3 2023 | 4.7% |
| ABBOTT LABS | 31 | Q3 2023 | 4.6% |
| ELEVANCE HEALTH INC | 31 | Q3 2023 | 4.3% |
| UnitedHealth Group Incorporated | 31 | Q3 2023 | 3.6% |
| ALNYLAM PHARMACEUTICALS INC | 31 | Q3 2023 | 3.7% |
| Boston Scientific Corporation | 31 | Q3 2023 | 2.5% |
View Bellevue Group AG's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G | 2023-02-14 |
| SC 13G | 2023-02-14 |
| 13F-HR | 2022-11-14 |
View Bellevue Group AG's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.